Diagnostic approach: clinical, biological, endoscopic, and histological findings
ACG 2025 key concept statements: suspicion, exclusion of infection, and colonoscopy with biopsy
ACG 2025 recommendations: Clostridioides difficile testing and serologic antibody testing
Endoscopy and histology: extent by the Montreal classification
“The diagnosis of UC requires a lower gastrointestinal endoscopic examination with histologic confirmation. For most patients, a complete colonoscopy and direct visualization of the terminal ileum should be performed.” (opens the source at this quote in a new tab)
“Endoscopically, UC most often presents as a continuously inflamed segment involving the distal rectum and extending proximally. Endoscopic features of inflammation include loss of vascular markings, granularity and friability of the mucosa, erosions, and in the setting of severe inflammation, deep ulcerations and spontaneous bleeding.” (opens the source at this quote in a new tab)
“The extent of the disease should be characterized according to the currently used Montreal classification as proctitis (E1, usually defined as ≤15 cm of inflammation), left-sided colitis (E2, defined as more than proctitis, but the extent stops at or distal to the splenic flexure), or extensive colitis (E3, defined as extension proximal to the splenic flexure, with pancolitis defining the entire rectum and colon including the cecum) (Figure 1) (33,34).” (opens the source at this quote in a new tab)
Biomarkers: fecal calprotectin, C-reactive protein, and serology
Disease activity assessment: Mayo score and the trial definition of moderately to severely active disease
“Several quantitative disease activity indices are available (64) including the Mayo score (Table 5) (65), Seo Index (66), Rachmilewitz Index (67), Simple Clinical Colitis Activity Index (SCCAI) (Table 6) (68), PRO2 (69), and the pediatric UC activity index (70).” (opens the source at this quote in a new tab)
“Inclusion criteria for clinical trials of agents for moderately to severely active UC have required components such as (i) inability to taper off prednisone, (ii) prior failure of immunosuppressants, and (iii) moderate-to-severe disease defined by Modified Mayo score (including the specific endoscopy subscore). In clinical trials, the definition of clinical remission has been a MES of 0 or 1, stool frequency of ≤1, and absence of rectal bleeding.” (opens the source at this quote in a new tab)
“The MES is frequently used in clinical trials and is simple to use in clinical practice, ranging from 0 for normal or inactive disease to 3 for severely active disease (65).” (opens the source at this quote in a new tab)
Intestinal ultrasound for monitoring disease activity
Diagnostic delay: mean 2.0 years from symptom onset